Abstract 1444P
Background
In the United States, uniquely American risk factors have led to a rise in the incidence of esophageal adenocarcinoma. In contrast, Asians have generally shown a predominance of esophageal squamous cell carcinoma (SCC), and this has held among Asian-Americans. However, limited investigation of esophageal cancer within Asian-Americans has been conducted in recent years.
Methods
The Surveillance, Epidemiology, and End Results (SEER) Incidence Database was queried for patients from 2004-2020 classified as Asian/Pacific Islander and diagnosed with esophageal adenocarcinoma or squamous cell carcinoma. Descriptive statistics and multivariate models were utilized to compare incidence, cancer characteristics, treatment details, and survival in patients with esophageal adenocarcinoma and SCC.
Results
During this time, 2103 (73.71%) Asian-Americans presented with esophageal SCC compared to 750 (26.29%) with adenocarcinoma. Patients with SCC were diagnosed at a significantly older age (68.09 vs 66.10, p=<0.0001) and had a larger distribution of females (28.72% vs 15.20%, p<0.0001) than those with adenocarcinoma. The distribution of tumor stage was significantly different across these two groups (p<0.0001), with 292 (38.93%) adenocarcinoma patients diagnosed at stage IV compared to 546 (25.96%) patients with SCC. Cox regression analysis revealed that SCC was independently associated with worse survival (Hazard Ratio 1.115 (1.08-1.233)) compared to esophageal adenocarcinoma. Table: 1444P
Histological subtype | p-value | ||
Squamous cell carcinoma (N = 2103), N (%) | Adenocarcinoma (N = 750), N (%) | ||
Age, mean (years) | 68.09 | 66.10 | <0.0001 |
Sex | <0.0001 | ||
Female | 604 (28.72) | 114 (15.20) | |
Male | 1499 (71.28) | 636 (84.80) | |
Derived stage | <0.0001 | ||
I | 196 (9.32) | 72 (9.60) | |
II | 379 (18.02) | 97 (12.93) | |
III | 547 (26.01) | 166 (22.13) | |
IV | 546 (25.96) | 292 (38.93) | |
Unknown | 435 (20.68) | 123 (16.40) | |
Location of tumor | <0.0001 | ||
Upper third | 276 (13.12) | 11 (1.47) | |
Middle third | 692 (32.91) | 43 (5.73) | |
Lower third | 547 (26.01) | 566 (75.47) | |
Unclear/NOS | 588 (27.96) | 130 (17.33) | |
Cause of death | <0.0001 | ||
Alive | 452 (21.49) | 177 (23.6) | |
Esophageal cancer | 1300 (61.82) | 411 (54.8) | |
Other cause of death | 351 (16.69) | 162 (21.6) |
Conclusions
SCC remains the predominant histological subtype of esophageal cancer within Asian-Americans. Several factors may contribute to this, including BMI, immigration history, and retained cultural practices. However, adenocarcinoma should not be missed in this cohort. The later stage diagnosis of adenocarcinoma suggests that methods to improve early detection are necessary, and poorer survival of the SCC cohort indicates an opportunity to improve treatment paradigms.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1446P - Efficacy and safety of cadonilimab combined albumin-paclitaxel, cisplatin and fluorouracil (APF) in neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma (LA-ESCC): Results from the CAPITAL trial
Presenter: Huiwen Miao
Session: Poster session 18
Resources:
Abstract
1447P - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study
Presenter: David Tougeron
Session: Poster session 18
Resources:
Abstract
1448P - IMHOTEP phase II trial of neoadjuvant pembrolizumab in dMMR/MSI localized cancers: Results of the digestive non-colorectal cancer cohorts
Presenter: Christelle de la Fouchardiere
Session: Poster session 18
Resources:
Abstract
1449P - Recurrent patient-reported outcome (PRO)-based symptomatic deterioration predicts progression-free survival (PFS): Results from RATIONALE-305
Presenter: Markus Moehler
Session: Poster session 18
Resources:
Abstract
1450P - Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial
Presenter: Georg Martin Haag
Session: Poster session 18
Resources:
Abstract
1451P - Neoadjuvant and adjuvant pembrolizumab (pembro) + chemotherapy (chemo) for locally advanced gastric or gastroesophageal junction (G/GEJ) cancer: Patient-reported outcomes (PROs) from the phase III KEYNOTE-585 study
Presenter: Kohei Shitara
Session: Poster session 18
Resources:
Abstract
1452P - Camrelizumab plus chemotherapy combined with consolidative radiotherapy as first-line treatment for oligometastatic esophageal squamous cell carcinoma (ESCORT-1ST-RT): A single-arm, open-label, phase II trial
Presenter: Wei Huang
Session: Poster session 18
Resources:
Abstract
1453P - A phase Ib study of AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC)
Presenter: Nan Bi
Session: Poster session 18
Resources:
Abstract
1454P - An open label phase II study of lenvatinib with pembrolizumab and FLOT in the neoadjuvant and adjuvant treatment for patients with gastric and gastroesophageal junction adenocarcinoma (EPOC2001)
Presenter: Akihito Kawazoe
Session: Poster session 18
Resources:
Abstract
1455P - Chemotherapy combined with cadonilimab (AK104) as neoadjuvant treatment for locally advanced gastric/gastroesophageal junction cancer: A prospective, single-arm, phase II clinical trial
Presenter: Pengfei Zhang
Session: Poster session 18
Resources:
Abstract